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ABSTRACT
Massively parallel DNA sequencing enables the detection of thousands of germline 
and somatic single nucleotide variants (SNVs) in cancer samples. The functional 
analysis of these mutations is often carried out through in silico predictions, with 
further downstream experimental validation rarely performed. Here, we examine 
the potential of using mass spectrometry-based proteomics data to further annotate 
the function of SNVs in cancer samples. RNA-seq and whole genome sequencing 
(WGS) data from Jurkat cells were used to construct a custom database of single 
amino acid variant (SAAV) containing peptides and identified over 1,000 such 
peptides in two Jurkat proteomics datasets. The analysis enabled the detection of 
a truncated form of splicing regulator YTHDC1 at the protein level. To extend the 
functional annotation further, a Jurkat phosphoproteomics dataset was analysed, 
identifying 463 SAAV containing phosphopeptides. Of these phosphopeptides, 24 
SAAVs were found to directly impact the phosphorylation event through the creation 
of either a phosphorylation site or a kinase recognition motif. We identified a novel 
phosphorylation site created by a SAAV in splicing factor SF3B1, a protein that is 
frequently mutated in leukaemia. To our knowledge, this is the first study to use 
phosphoproteomics data to directly identify novel phosphorylation events arising from 
the creation of phosphorylation sites by SAAVs. Our study reveals multiple functional 
mutations impacting the splicing pathway in Jurkat cells and demonstrates potential 
benefits of an integrative proteogenomics analysis for high-throughput functional 
annotation of SNVs in cancer.
INTRODUCTION
DNA sequencing technologies have enabled the 
rapid identification of single nucleotide variants (SNVs) 
within cancer genomes. Hundreds to thousands of non-
synonymous SNVs can now be routinely identified within 
gene coding regions of individual cancers through whole 
genome or exome sequencing (WGS/WXS) [1], and 
expressed SNVs can also be detected by RNA sequencing 
(RNA-seq) [2]. To determine whether these SNVs are 
functionally important in cancer, in silico functional 
annotation tools are often used. This serves to reduce the 
total numbers of SNVs that are considered in downstream 
data analysis. However, experimental validation of the role 
that these SNVs have on protein structure and function 
remains a major challenge and therefore is not typically 
performed in routine analyses.
The detection of a SNV translated at the protein 
level is often the first step taken to infer whether the 
SNV is functional. Mass spectrometry-based proteomics 
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experiments are now capable of detecting thousands 
of proteins in a single experiment. Recent studies have 
shown that by integrating SNV calls from WXS or RNA-
seq data, it is possible to generate a sample-specific 
reference protein database that can be used to query a 
sample-matched proteomics dataset. For example, RNA-
seq data from two colon cancer cell lines have been used 
to generate customised databases containing single amino 
acid variants (SAAVs) which can be applied to search the 
respective proteomics data [3]. This study identified an 
additional 37 and 17 peptides in the SW480 and RKO 
cell lines, respectively. More recently, Sheynkman et 
al. [4], similarly generated a customised database with 
SAAVs for the Jurkat cell line using RNA-seq data. 
This customised database enabled the detection of 395 
SAAVs against a trypsin digested LC-MS/MS dataset. 
In a larger scale analysis by The Cancer Genome Atlas 
(TCGA) [5], 86 colorectal cancer proteomics datasets 
were searched against customised databases consisting of 
variants detected from sample-matched RNA-seq data. In 
this study, despite the large sample size, only 796 SAAVs 
were detected across 86 samples. A possible reason for 
this is that the RNA-seq data for TCGA colorectal cancer 
samples were not sufficiently deep for calling single 
nucleotide variants (SNVs) (~10M 50bp single end reads 
versus ~100M 100 bp paired-end reads for the Jurkat 
dataset from Sheynkman et al. [4]). Furthermore, the 
proteomics data was generally of lower depth than the 
Jurkat dataset (~100K spectra per sample versus ~500K 
spectra for the Jurkat dataset).
These studies have clearly demonstrated the 
ability to detect and quantify SAAV containing peptides. 
Nevertheless, how the detection of SAAVs at the protein 
level can benefit downstream analyses of protein function 
remains to be fully demonstrated. In this study, we 
first assess the potential of using an ‘ultra-deep’ Jurkat 
proteomics dataset to increase the number of SAAV 
containing peptides identified. We use several strategies 
to evaluate the accuracy of these SAAV containing 
peptides. Finally, to further demonstrate the potential 
of proteogenomics, we use a Jurkat phosphoproteomics 
dataset to show that this data can be used to directly 
identify SNVs that create novel protein phosphorylation 
events. Through this analysis, we highlight and discuss 
candidate SNVs that may play a role in the leukaemogensis 
of Jurkat cells.
RESULTS AND DISCUSSION
SAAV containing peptides detected in Mertins 
and Sheynkman jurkat datasets
A flowchart of the data analysis pipeline used 
is shown in Figure 1A. Of the 42,471 SNVs detected 
from the RNA-seq dataset, 7,284 were annotated as 
non-synonymous and 211 as stop gain substitutions 
(Supplementary Table 1). Using these SNVs, a customised 
protein database was generated and, along with the human 
reference proteome, was used to search the Sheynkman 
dataset (Supporting Data). In total, 378 SAAV containing 
peptides from 358 unique SAAVs were detected from 
the Sheynkman dataset (Supplementary Table 2). This 
is slightly less than the number of previously reported 
SAAVs containing peptides (n = 421) and unique SAAVs 
(n = 395) using the same data [4].
As the aim of this study was to identify functional 
SNVs, we examined how the use of higher depth 
proteomics data can increase the number of candidates. 
To achieve this, the Mertins dataset, which has over 2 
million (i.e. 500%) more tandem mass spectra than the 
Sheynkman dataset, was analysed similarly. In total, 1,048 
SAAV containing peptides, consisting of 929 unique 
SAAVs, were identified (Supplementary Table 3). The 
majority (72.9%, n = 239/328) of unique SAAVs detected 
from the Sheynkman dataset overlapped with the SAAVs 
detected from the Mertins dataset (Figure 1B). However, 
an additional 681 SAAVs could now be identified from 
the Mertins dataset. This represents an increase of almost 
three times as many SAAVs detected, when compared 
with the Sheynkman dataset (920 versus 328). Across 
both datasets, SAAV containing peptides consisted of 
0.61% (378/62,204) and 0.70% (1,048/150,159) of the 
total peptides detected from the Sheynkman and Mertins 
datasets, respectively.
Comparison between SAAV detection using 
variants from RNA-seq and whole genome 
sequencing (WGS) data
Variant calling using RNA-seq data can result in 
not detecting all variants in exonic regions since it is 
only able to detect SNVs in expressed genomic regions. 
Furthermore, studies have shown that RNA-seq data 
can also have higher false positive detection rates when 
compared with DNA sequencing due to mismatches 
arising from RNA to cDNA conversion during RNA 
sequencing library preparation as well as the complexities 
associated with precise alignment of reads spanning 
spliced junctions. To determine whether RNA-seq SNV 
detection is adequate, with regard to the goal of identifying 
SAAV containing peptides, we sought to compare the use 
of SNVs from RNA-seq and WGS.
The genome of the Jurkat dataset was recently whole 
genome-sequenced at 60X coverage [6]. To enable a more 
direct comparison of the RNA-seq and WGS data, we 
only considered exonic regions (Methods). Within exonic 
regions, 79,601 SNVs were detected of which 10,852 were 
non-synonymous or stop-gain variants from the WGS 
data (Supplementary Table 4). When compared with the 
non-synonymous or stop-gain SNVs from the RNA-seq 
dataset, 4,674 SNVs overlapped, representing 64.1% of all 
RNA-seq SNVs (Figure 2A). The higher number of SNVs 
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found across exonic regions in the WGS data compared 
with the RNA-seq data is expected as the RNA-seq data 
only covers transcribed regions.
To determine whether the higher number of variants 
from the WGS data would result in a greater number 
of SAAV peptides being discovered, we searched the 
Mertins proteomics dataset using a custom database 
generated using the WGS SNVs. Despite the larger search 
database, only 686 SAAVs could be identified using the 
WGS custom SAAV peptide database compared with 
930 identified from the corresponding RNA-seq custom 
SAAV peptide database (Figure 2B). The overlap of 
SAAV peptides was substantial with 97.1% (666/686) 
of the peptides identified from the WGS custom SAAV 
peptide database also present in the search using the RNA-
seq custom SAAV database. Examination of the genomic 
positions of the SNVs corresponding to the SAAV peptides 
identified that are unique to the custom RNA-seq database 
showed that the median coverage in the WGS data was 
just 3 reads and overall had significantly less coverage 
than SNVs corresponding to SAAV peptides common to 
both RNA-seq and WGS databases (Figure 2C, p < 0.0001 
Mann-Whitney test). This suggests that, in this case, 
SNVs from RNA-seq data provides a better reference 
proteomics datasets compared with WGS, where read 
coverage is generally lower. In particular, RNA-seq read 
coverage is enriched within highly expressed transcripts, 
Figure 1: Analysis of RNA-seq variants in proteomics datasets. (A) Schematic illustration of the RNA-seq/Mass spectrometry-
based variant peptide detection pipeline. (B) Overlap of unique SAAVs detected in the Mertins and Sheynkman datasets.
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meaning that it would be more sensitive in detecting SNVs 
corresponding SAAV due to the higher protein abundance.
Evaluation of SAAVs containing peptide 
identifications
To demonstrate that the SAAV containing 
peptides that we identified are true positives, we further 
performed a series of control analyses. Firstly, the SAAV 
containing peptides common to both RNA-seq and WGS 
SNV databases were classified as “heterozygous” or 
“homozygous” based on the variant allele frequency of the 
corresponding SNV derived from the WGS data. In total, 
we detected 274 “homozygous” (variant allele frequency 
(VAF) = 1.0) and 516 “heterozygous” SAAV containing 
peptides. Of the 274 “homozygous” SAAV containing 
peptides, we found 7 peptides with a corresponding 
reference peptide detected. This is unexpected as only a 
single sequence should be present at homozygous alleles. 
Further examination of the WGS sequence coverage 
showed that these SNVs had low coverage (alternate allele 
count < 10, Table 1). Examination of the corresponding 
RNA-seq data shows that these SNVs are in fact 
heterozygous with a variant allele frequency between 0.47 
and 0.64 (Table 1).
In contrast, for the 516 “heterozygous” SAAV 
containing peptides, a much higher proportion of peptides 
(n=355) had the corresponding reference sequence 
detectable (Supplementary Table 5). The discrepancy 
between the number of reference sequence peptides 
corresponding to the SAAV containing peptides detected 
can be attributed to the stochastic nature of peptide 
sampling by mass spectrometers [7]. Nevertheless, the 
proportion of “heterozygous” SAAV containing peptides 
with the corresponding reference peptide detected was 
significantly higher (p < 0.0001, Fisher’s exact test) than 
the “homozygous” SAAV containing peptides.
The detection of the 355 reference peptides with 
a corresponding SAAV containing peptide allows the 
abundance of the corresponding peptides to be directly 
compared. Given that the corresponding SNVs are 
heterozygous, it would be expected that the abundance 
of the two alleles would be similar. Indeed, a clear 
correlation between the abundance of the reference and 
the corresponding SAAV containing peptide can be seen 
(R=0.6632, Figure 3A). This suggests that the two alleles 
of most heterozygous SNVs are co-transcribed and co-
translated under the same regulatory mechanisms.
Finally, as the 1,010 SAAVs detected by mass 
spectrometry represent only 13.9% (n = 1,010/7,284) of all 
non-synonymous and nonsense SNVs detected by RNA-
seq, we compared the read depth of SNVs corresponding 
to SAAV containing peptides with all remaining SNVs. 
The read depth in RNA-seq of identified SNVs was 
significantly higher than unidentified SNVs (median 194 
versus 42 reads, p < 0.001, Mann-Whitney test) (Figure 
3B). This suggests that SNVs that are in more highly 
expressed transcripts are more likely to be detected as 
SAAVs by mass spectrometry as the corresponding protein 
is also more abundant.
Inclusion of variant peptides impacts protein 
quantification
Accurate protein quantification relies on the 
assumption that all proteolytic peptides are being detected 
and quantified. Standard database searches do not 
detect and include SAAV containing peptides in protein 
quantification. Thus, we examined whether the inclusion 
of SAAV containing peptides in the calculation of protein 
Figure 2: Comparison of RNA-seq and WGS variants for proteomics. (A) Overlap of unique SAAVs detected in the Mertins 
dataset using RNA-seq SNVs and WGS SNVs. (B) Distribution of WGS read coverage of SAAVs that were unique to the RNA-seq SNV 
dataset or common to both the WGS and RNA-seq SNV datasets.
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abundance may impact upon protein quantification 
accuracy. We used the Sheynkman dataset for this analysis, 
as the RNA-seq and proteomics data were generated from 
the same cells [8]. Using the Sheynkman dataset, we found 
good concordance between iBAQ and the RNA-Seq based 
expression values (R=0.68230).
In total, 378 proteins contained SAAV containing 
peptides. Correlation of the updated iBAQ values 
incorporating the intensity of SAAV containing peptides 
(see Methods) across all proteins (n = 6,881) with the 
corresponding mRNA expression value showed a modest 
but significant (p<0.01, Williams’ (1959) t-test) increase 
in correlation coefficient (R = 0.6825 to R= 0.6830; 
Figure 4A, 4B). To more clearly illustrate the impact of 
the updated iBAQ values, we calculated the correlation of 
the updated iBAQ values specifically for the 318 proteins 
with SAAV containing peptides. In this case, the mRNA 
expression value showed a more significant (p<0.0001, 
Williams’ (1959) t-test) increase in correlation coefficient, 
from R = 0.6978 to R = 0.7154 (Figure 4C, 4D). Although 
mRNA expression level is not an accurate measure of 
protein expression [9], the improved correlation that we 
Table 1: Homozygous SNVs where a reference peptide was identified by mass spectrometry








MVWDSQVSEHFFEYKK MVWDSQASEHFFEYKK NM_001142677 p.A307V 0.634 (45) 1.00 (3) 122,530,000 29,178,000
SQLPDLSAPHSYSPGR SQLPDLSGPHSYSPGR NM_015114 p.G891A 0.615 (120) 1.00 (2) 469,400,000 339,370,000
QVPPDLFQPYTEEICQNLR QVPPDLFQPYIEEICQNLR NM_001619 p.I150T 0.535 (385) 1.00 (2) 22,980,000 96,743,000
SGVHVVVTGPPNAGK SGAHVVVTGPPNAGK NM_133644 p.V282A 0.506 (42) 1.00 (3) 797,570,000 64,056,000
YHSLPPMYYR YHSLAPMYYR NM_001252036 p.A86P 0.503 (94) 1.00 (5) 27,447,000 482,390,000
TGSTLVQR TGSALVQR NM_002675 p.A331T 0.491 (26) 1.00 (9) 1,232,100,000 1,585,200,000
ADGTPITQSVEMTTPSK ADGTPITQGVEMTTPSK NM_020070 p.G159S 0.471 (120) 1.00 (2) 220,560,000 140,030,000
Figure 3: Evaluation of properties of SAAV containing peptides. (A) Correlation between the abundance of SAAV containing 
peptides and its corresponding reference peptide from the Mertins dataset. A total of 467 peptides were paired in the comparison. (B) 
Comparison of the depth of RNA-seq read coverage of SNVs identified by the corresponding SAAV containing peptide by mass spectrometry 
and unidentified SNVs (p < 0.0001, Mann-Whitney test). Error bars represent 10-90 percentile.
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observed over a pool of hundreds of proteins suggests 
that the inclusion of SAAV containing peptides in protein 
quantification may be beneficial to the accuracy of 
quantitative proteomics experiments.
Truncation of YTHDC1 is a potential candidate 
cancer driver mutation in Jurkat cells
In order to determine whether the use of proteomics 
data can help the identification of candidate cancer driver 
mutations, we sought to prioritise SNVs that are most 
likely to alter protein function. Examination of the list of 
SAAVs (Supplementary Table 2 & 3) reveals that there is 
only one stop gain event that can be detected across both 
the Sheynkman and Mertins datasets. This SAAV results 
in the truncation of YTHDC1 at G589 (Figure 5A) and 
the identification is supported by manual examination 
of the tandem mass spectrum (Figure 5B). YTHDC1 is a 
regulator of alternative splicing that specifically recognises 
and binds N6-methyladenosine (m6A)-containing RNAs 
[10-12]. The truncation of YTHDC1 removes an arginine-
rich region at the C-terminus of the protein (Figure 5C). 
As arginine-rich motifs in proteins are generally known 
to be important in RNA binding [13], this truncation may 
impact the RNA binding ability of YTHDC1.
Based on the RNA-seq data, the variant is 
heterozygous (Supplementary Table 5) but is completely 
absent from the Exome Aggregation Consortium (ExAC) 
database [14], suggesting that it is likely to be a somatic 
mutation in the Jurkat cell line. Examination of known 
somatic mutations in YTHDC1 from the Catalog of 
Somatic Mutations in Cancer (COSMIC) database shows 
a relatively large number of stop gain mutations over the 
protein (Supplementary Table 6). Of all COSMIC samples 
with point mutations in YTHDC1, 14.1% (24/170) of 
mutations are stop-gain mutations which are significantly 
more than in all genes in general (p < 0.0001, chi-square 
test, Supplementary Table 6). Many of the truncations 
occur within <25 amino acids of the G589* mutation 
(Figure 5C). Tumour suppressor genes tend to have a 
Figure 4: Impact of SAAV containing peptides on protein quantification. Comparison of the correlation between protein 
abundance and mRNA expression in the Jurkat cell line before (A) and after (B) inclusion of SAAV containing peptides for all 6,881 
proteins. Comparison of only 318 proteins that contain SAAVs before (C) and after (D) inclusion of the SAAV containing peptides.
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relatively high percentage of stop gain mutations [15]. 
For instance, the percentage of substitution mutations that 
are stop-gain for some well-known tumour suppressor 
genes such as MLH1, PTEN and VHL are 13.6% (37/272), 
29.3% (657/2,242) and 20.3% (250/1,229), respectively. 
While, to our knowledge, YTHDC1 mutations have not 
previously been implicated in leukaemia, mutations 
affecting splice factors are common in leukaemia [16, 
17] and myelodysplastic syndromes [18]. Thus, the 
G589* stop gain mutation in YTHDC1 may contribute to 
leukaemogenesis in Jurkat cells by impacting the RNA 
splicing pathway.
Table 2: Summary of datasets used in study
Experiment Details Reference
RNA-seq ~ 100 M, 100 bp PE reads [8]
Whole genome sequencing ~900 M, 150 bp PE reads [6]
Proteomics deep
(Sheynkman proteomics dataset)
~ 0.5 M spectra [8]
Proteomics ultra-deep
(Mertins proteomics dataset)
~ 2.5 M spectra [25]
Proteomics ultra-deep PTM
(Mertins phosphoproteomics dataset)
STY(p) - ~ 0.85 M spectra [25]
STY(p) – phosphorylation of S, T or Y
Figure 5: Truncation mutation in YTHDC1. (A) Illustration of the C>A/G>T SNV at chr4:69184242 (boxed in red) on the YTHDC1 
gene resulting in a G589* SAAV. The tryptic peptide EFHNMGPPPPWQ detected as a result by mass spectrometry is underlined in black. 
(B) Representative tandem mass spectrum of the doubly charged ion of EFHNMGPPPPWQ. (C) Mutation map of COSMIC mutations 
across YTHDC1 showing the YTH domain and arginine (Arg) rich regions.
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Novel phosphorylation sites created by SNVs
Having established that potential cancer-associated 
SNVs can be inferred from proteomics data, we further 
investigated the use of phosphoproteomics data in more 
directly identifying SNVs that can alter the phosphorylation 
state of a protein. Using the SAAV peptide database, we applied 
MaxQuant [19] to analyse the Mertins phosphoproteomics 
dataset (Table 2). In total, we identified 462 MS/MS spectra of 
SAAV containing phosphopeptides, representing 1.11% of the 
total phosphopeptide MS/MS spectra detected in the dataset 
(462/41,698) (Supplementary Table 7).
Figure 6: Phosphorylation sites created by SNVs. (A) Phosphopeptides that were detected as a result of the inclusion of SAAVs 
into the search database, classified into one of 3 categories including, no impact of phosphorylation site, creation of phosphorylation 
site and the creation of a phosphorylation motif. (B) Tandem mass spectrum of quadruply charged SF3B1 tryptic phosphopeptide 
KPGYHpTPVALLNDIPQSTEQYDPFAEHRPPK containing the A85T SAAV.
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The inclusion of SAAVs within the search space can 
influence the detection of different phosphorylation events. 
For example, (1) the SAAV may create an amino acid that 
allows a novel phosphorylation site to form, (2) the SAAV 
may create a motif that allows a novel phosphorylation 
event to take place, and (3) the SAAV may not impact 
the formation of the phosphorylation event, but instead 
may simply add the SAAV into the protein database, thus 
allowing the SAAV-containing phosphopeptide to be 
detected. To this end, the phosphopeptides were examined 
further to determine to which of the three categories 
described above, each one belonged. In this case, to 
determine motif creation, we only considered proline-
directed kinases such as mitogen-activated protein kinases 
(MAPK) and cyclin-dependent protein kinases (CDK) [20] 
as these have a simple and clearly defined phosphorylation 
motif ([S/T]P). As such, if a SAAV creates a proline that 
is immediately C-terminal of a serine or threonine, we 
considered that the gain of this proline was responsible 
for the phosphorylation of the N-terminally adjacent serine 
or threonine.
Based on the 3 categories outlined above, each of the 
462 SAAV phosphopeptides was categorised. We found 
that only a minority (5.2%, 24/462) of SAAVs created 
a phosphorylation event, whereas the majority simply 
enabled the detection of an existing phosphorylation event 
(Figure 6A). A summary of the SAAVs that created a 
phosphorylation site or a phosphorylation motif is shown 
in Table 3. Of the 24 SAAV sites that either created a 
phosphorylation site or a phosphorylation, only five do 
not correspond to known SNPs and are therefore likely to 
be somatic mutations (Table 3). One of these five putative 
somatic SAAVs results in the phosphorylation of T86 in 
the splicing factor 3b subunit 1 (SF3B1) protein. Manual 
examination of the tandem mass spectrum further confirmed 
the identification of this phosphopeptide (Figure 6B).
Table 3: List of phosphopeptides that have been detected as a result of a gain of phosphorylation site (grey), or 
a gain of a phosphorylation motif (white). Phosphorylation residue is indicated by bold and the SAAV residue is 
underlined.
Gene SAAV Peptide Genomic coordinates (hg19) dbSNP ID ExAc allele freq.
ATP5A1 p.A126S VGLKSPGIIPR chr18:43669656 NA 0.0000
SGK223 p.G1222S QKPGSTPNLQQK chr8:8176221 rs13269488 0.5286
TANC1 p.N250S SGSSLEWNKDGSLR chr2:160019863 rs12466551 0.9907
TADA2A p.P6S LGSFSNDPSDKPPCR chr17:35771468 rs7211875 0.8597
ATP5SL p.N40S LGAAVAPEGSQKK chr19:41944237 rs2231940 0.4053
GBF1 p.G1690S GGSPSALWEITWER chr10:104140350 rs11191274 0.0972
PCM1 p.N159S DASTSPPNRETIGSAQCK chr8:17796382 rs41364448 0.7324
PCM1 p.N159S SKDASTSPPNRETIGSAQCK chr8:17796382 rs41364448 0.7324
SPDL1 p.L586S SHPILYVSSK chr5:169031150 rs3777084 0.6613
DDX27 p.G766S ASPSFEER chr20:47859217 rs1130146 0.3498
GPANK1 p.A78S IMKSPAAEAVAEGASGR chr6:31632024 NA 0.0000
SF3B1 p.A86T KPGYHTPVALLNDIPQSTEQYDPFAEHRPPK chr2:198285797 NA 0.0000
MEX3A p.A430T SPTTSAGPELAGLPR chr1:156046640 NA 0.0000
LMO7 p.M1162T YLDQIGNTTSSQRR chr13:76423248 rs7986131 0.7203
RMI1 p.N455S SSQISNENDCNLQSCSLR chr9:86617265 rs1982151 0.7152
ICE1 p.C391S NSAESVSEDDTTESQNYFGSLR chr5:5460619 rs2619844 0.6964
LAT p.P253S TEPAALSSQEAEEVEEEGASDYENLQELN chr16:29001301 NA 0.0000
PNPLA6 p.A403P ETPGRPPDPTGAPLPGPTGDPVKPTSLETPSPPLLSR chr19:7606908 rs17854645 0.1651
DMXL2 p.S1288P FGDTEADSPNAEEAAMQDHSTFK chr15:51791559 rs12102203 0.4925
KIAA0586 p.L703P EASPPPVQTWIK chr14:58937416 rs1748986 0.9916
GGA2 p.A424P NLLDLLSPQPAPCPLNYVSQK chr16:23489711 rs1135045 0.7564
ZNF235 p.H296P SPACSTPEKDTSYSSGIPVQQSVR chr19:44792701 rs2125579 0.5206
BRIP1 p.S919P YSTPPYLLEAASHLSPENFVEDEAK chr17:59763347 rs4986764 0.5972
SHF p.A242P ETATQPLPLYDTPYEPEEDGATPEGEGAPWPR chr15:45467540 rs1632144 0.9763
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SF3B1 is involved in the regulation of splicing 
as part of the splice factor complex. SF3B1 is a known 
phosphoprotein [21] and the phosphorylation of SF3B1 has 
also been shown to be associated with splicing activation 
[22]. However, little is known about how phosphorylation 
of sites in SF3B1 alters its activity. It may be possible that 
the phosphorylation of T86 that we identified modulates 
the activity of SF3B1. As with the stop-gain SNV in 
YTHDC1, analysis of the allele frequency of this SF3B1 
SNV in the ExAc database [14] shows that it is not present 
in the general population (Table 3) further suggesting this 
SNV is a somatic mutation.
CONCLUSIONS
SNVs that lead to the creation of novel 
phosphorylation sites have previously been described in 
several studies. For example, the germline R405S variant 
in androgen receptor (AR) has been shown to result in 
the phosphorylation of S405 and this post-translational 
modification results in the disruption of protein-protein 
interactions between AR and EP300 [23]. In the context 
of cancer, in silico methods have been applied to predict 
the gain of phosphorylation from somatic mutations 
[24]. However, to our knowledge, ours is the first study 
to have used phosphoproteomics data to directly identify 
novel phosphorylation events arising from the creation of 
phosphorylation sites by SAAVs.
In summary, by integrating RNA-seq and 
proteomics data, we have shown that the translation of 
some SNVs can be detected at the protein level, and this 
can allow more accurate inference to the functional impact 
of mutations. Although our analysis does not enable direct 
inference of whether particular variants play a direct role 
in causing cancer, we have demonstrated that it can be 
used to further prioritise candidate SNVs. In this case, 
we found two SNVs which both affect the RNA splicing 
pathway in Jurkat cells. As splicing factor mutations are 
common in blood disorders [16-18], these mutations may 
play an important role in the leukaemogenesis. Uniquely, 
out study has also demonstrated that the integration of 
RNA-seq data with phosphoproteomics data can be used 
to directly discover novel phosphorylation events. With 
massively parallel sequencing and proteomics becoming 
increasingly commonplace, such analyses will likely 
become increasingly useful for cancer research.
MATERIALS AND METHODS
Data sources
The Jurkat (T-cell acute lymphocytic leukaemia) 
cell line RNA-seq data [8] were obtained from Gene 
Expression Omnibus (GSE: GSE45428) in SRA format. 
Matched deep LC-MS/MS Jurkat proteomics dataset 
[8] in RAW format were obtained from PeptideAtlas 
under the accession PASS00215. This is referred to in 
the manuscript as the Sheynkman proteomics dataset. 
Both ‘Ultra-deep’ and phosphorylation-enriched Jurkat 
proteomics datasets [25] were obtained in RAW format 
from MassIVE (MSV000078509). These are referred to 
in the manuscript as the Mertins proteomics dataset and 
phosphoproteomics dataset, respectively. Variant calls and 
aligned Jurkat whole genome sequencing data [6] were 
obtained from Zenodo (400615) and the NCBI Sequence 
Read Archive (SRA) (SRP101994), respectively. A list of 
datasets used in this study, together with their properties 
and sources are summarised in Table 2. COSMIC [26], 
ExAc [14] and dbSNP databases were used to assess SNV 
frequency and distribution.
Variant calling from RNA-seq and WGS dataset
The Jurkat RNA-seq data in SRA format were 
converted to fastq, trimmed using sickle (version 1.33) 
and aligned using tophat (version 1.4.0) [27]. Samtools 
mpileup [28] was used for variant calling from the RNA-
seq data. A variant filter was applied where SNVs with 
less than 2 reads and a mapping quality score of less 
than 10 were removed. Furthermore, to allow for a direct 
comparison of the variants called within exonic regions of 
the human genome, only variants that were present within 
exons, as defined by the RefSeq database, were kept for 
further analysis. This resulted in the detection of 42,471 
SNVs. For the WGS data, only variant calls that were 
annotated as PASS and overlapped the RefSeq exons were 
used for further analysis. This resulted in 79,601 SNVs. 
To determine the reference and alternative allele count in 
the WGS dataset, samtools mpileup was used on the WGS 
BAM file obtained from SRA as described above.
Generation of proteomics databases
To facilitate simple and accurate mapping of 
SNPs to SAAVs in proteins, the human Refseq protein 
annotations were used, as both the human proteome 
database, and for variant annotation. Annotation of 
SNPs against Refseq was performed using ANNOVAR 
[29]. To create the human Refseq proteome database in 
fasta format, the RefFlat GTF file was obtained from the 
Illumina iGenomes resource and the gffread utility (https://
github.com/gpertea/gffread) was used to translate the 
transcripts defined in the GTF file into protein sequences.
In order to generate the custom SAAV database, a 
Python script was written to directly map SAAVs from 
the ANNOVAR annotated SNPs and to output theoretical 
tryptic peptides up to 1 missed cleavage either side of the 
SAAV.
Processing of proteomics data
LC-MS/MS data in RAW format were analysed 
using MaxQuant (version 1.3.5.8) [19]. The data was 
Oncotarget95851www.impactjournals.com/oncotarget
searched using a “two-stage” strategy [30], where 
the LC-MS/MS data was first searched using human 
Refseq proteome and contaminant proteins and then 
subsequently, the remaining unidentified spectra 
were searched using the RNA-seq or WGS custom 
SAAV database. At each stage, a reversed decoy 
database was included for false discovery estimation. 
For all searches, carbamidomethyl (C) was selected 
as a fixed modification while oxidation (M) and 
acetylation (protein N-term) were selected as variable 
modifications. For searching of the phosphoproteomics 
dataset, phosphorylation (STY) was selected. For all 
searches, the mass tolerance was set at 10 ppm and 
false discovery rate set at 0.01. In the case of the 
phosphoproteomics dataset, only phosphorylation sites 
with a localisation score of ≥ 0.75 were retained for 
further analysis.
Protein quantitative analysis
For protein quantitative analysis, the peptide ion 
intensity and the iBAQ quantitative value were obtained 
from MaxQuant. To calculate new updated protein iBAQ 
values incorporating SAAV containing peptides, the ion 
intensity of SAAV containing peptides was added to 
the respective protein’s total ion intensity. The updated 
iBAQ value was calculated by dividing the updated total 
intensity value by the number of theoretically detectable 
peptides.
For the comparison of RNA expression to protein 
abundance, RNA expression was measured as Reads 
Per Kilobase of transcript per Million mapped reads 
(RPKM). To compare the significance of the change in the 
correlation of RNA and protein abundance before and after 
inclusion of SAAV containing peptides, significance was 
determined using the Williams’ (1959) t-test, calculated 
with the R package cocor [31].
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